T-Cell Immunotherapy Market, 2030 - Focus on CAR-T Therapies, TCR Therapies and TIL Therapies


Dublin, Sept. 19, 2018 (GLOBE NEWSWIRE) -- The "T-Cell Immunotherapy Market (3rd Edition), 2018-2030" report has been added to ResearchAndMarkets.com's offering.

The "T-Cell Immunotherapy Market, 2018-2030 (3rd edition)" report features an extensive study of the current market landscape and the future potential of T-cell immunotherapies (focusing particularly on CAR-T therapies, TCR therapies and TIL therapies). One of the key objectives of the study was to review and quantify the future opportunities associated with the ongoing development programs of both small and big pharmaceutical firms.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2018-2030. The report includes potential sales of T-cell immunotherapies that are currently marketed or are in late stages of development.

Additionally, the chapter presents a detailed market segmentation on the basis of type of therapy (CAR-T, TCR and TIL), geography (North America, Europe and Asia Pacific) and target indications (acute lymphoblastic leukemia, acute myeloid leukemia, bladder cancer, cervical carcinoma, chronic lymphocytic leukemia, esophageal cancer, head and neck cancer, multiple myeloma, hepatocellular carcinoma, melanoma, non-Hodgkin's lymphoma, non-small cell lung cancer, ovarian cancer and synovial sarcoma). To account for the uncertainties associated with the development of these novel therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

Amongst other elements, the report features the following:

  • An analysis depicting prevalent and emerging trends related to T-cell immunotherapies as observed on the social media platform, Twitter. In addition to the yearly chatter trends, the analysis highlights the most frequently talked about product candidates.
  • A detailed assessment of the current market landscape of T-cell immunotherapies with respect to type of therapies, type of developer (industry/non-industry), phase of development, target therapeutic indications, key target antigens, source of T-cells (autologous and allogenic), and route of administration. In addition, we have provided an overview of the competitive landscape, key challenges and anticipated future trends associated with T-cell based therapies.
  • Comprehensive profiles of marketed and mid to late stage clinical products (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.
  • An analysis of the CAR constructs of clinical CAR-T therapies based on generation of CAR-T therapy (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of vector and type of co-stimulatory domain used.
  • An analysis of the global CAR-T clinical trials registered between 2009 and 2018, highlighting the year wise trend and the distribution across different geographies.
  • An overview of the various focus therapeutic areas of therapy developers, including an assessment of the opportunity offered by oncological and non-oncological disease indications.
  • A detailed discussion on innovative technology platforms that are being used for the development of T-cell therapies, along with profiles of key technology providers.
  • An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements and others.
  • An analysis of the investments that have been made into companies that have proprietary products/technologies, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing.
  • A case study on other T-cell based therapies, apart from CAR-Ts, TCRs and TILs. It presents a detailed analysis of the approved/pipeline products in this domain, including information on the current phase of development, target therapeutic areas, type of T-cells used, and source of T-cells.
  • A case study on manufacturing cell therapy products, highlighting the key challenges, and a list of contract service providers and in-house manufacturers that are involved in this space.
  • An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models/approaches that a pharmaceutical company may choose to adopt to decide the price of a T-cell based immunotherapy that is likely to be marketed in the coming years.
  • A review of the key promotional strategies that have been adopted by the developers of the marketed T-cell therapies, namely Kymriah and Yescarta.

Key Topics Covered:

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Immunotherapy, an Emerging Therapeutic Option
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.1.1. Active Immunotherapy
3.5.1.2. Passive Immunotherapy
3.5.2. By Type of Target
3.5.3. By Approach
3.5.4. By Product Class
3.5.4.1. Monoclonal Antibodies
3.5.4.2. Bispecific Antibodies
3.5.4.3. Cytokines
3.5.4.4. Oncolytic Virus Therapy
3.5.4.5. Therapeutic Cancer Vaccines
3.5.4.6. Cell-based Therapies
3.6. Historical Evolution of T-Cell Immunotherapies
3.7. Key Considerations of T-Cell Immunotherapies
3.8. Strategies Employed for Redirection of T-Cells
3.9. Manufacturing of Engineered T-Cells
3.10. T-Cell Transduction/Transfection Methods
3.10.1. Retroviral Vectors
3.10.2. Lentiviral Vectors
3.10.3. Non-viral Transfection Methods
3.11. Therapeutic Areas Targeted by T-Cell Immunotherapies
3.12. Key Challenges of T-Cell Immunotherapies

4. EMERGING TRENDS ON SOCIAL MEDIA
4.1. Chapter Overview
4.2. Trends on Twitter
4.2.1. T-Cell Immunotherapies: Yearly Trends on Twitter
4.2.2. T-Cell Immunotherapies: Popular Keywords on Twitter
4.2.3. T-Cell Immunotherapies: Most Popular Drugs on Twitter

5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. T-Cell Immunotherapies: A Promising Pipeline
5.2.1. T-Cell Immunotherapies: Distribution by Type of Product
5.2.2. T-Cell Immunotherapies: Distribution by Type of Developer
5.2.3. T-Cell Immunotherapies: Distribution by Phase of Development
5.2.4. T-Cell Immunotherapies: Target Oncological Indications
5.2.4.1. CAR-T Immunotherapies: Popular Target Indications
5.2.4.2. TCR Immunotherapies: Popular Target Indications
5.2.4.3. TIL Immunotherapies: Popular Target Indications
5.3.5. T-Cell Immunotherapies: Popular Target Antigens for CAR-T and TCR Therapies
5.3.6. T-Cell Immunotherapies: Distribution by Source of T-Cells
5.3.7. T-Cell Immunotherapies: Distribution by Route of Administration
5.3.8. T-Cell Immunotherapies: Key Industry Players
5.3.9. T-Cell Immunotherapies: Key Non-Industry Players

6. KEY INSIGHTS
6.1. Chapter Overview
6.2. T-Cell Immunotherapies: Analysis by Popularity of Target Antigens
6.2.1. Hematological Cancer: Popular Targets
6.2.1.1. CD19 CAR-T Immunotherapies: Competitive Landscape
6.2.1.2. CD19 CAR-T Immunotherapies: Clinical Trial Results of Prominent Product Candidates
6.2.1.3. BCMA CAR-T Immunotherapies: Competitive Landscape
6.2.1.4. BCMA CAR-T Immunotherapies: Clinical Trial Results of Prominent Product Candidates
6.2.2. Solid Tumors: Popular Targets
6.2.2.1. Meso CAR-T Immunotherapies: Competitive Landscape
6.2.2.2. Meso CAR-T Immunotherapies: Clinical Trial Results of Prominent Product Candidates
6.2.2.3. GD2 CAR-T Immunotherapies: Competitive Landscape
6.2.2.4. GD2 CAR-T Immunotherapies: Clinical Trial Results of Prominent Product Therapies
6.3. T-Cell Immunotherapies: CAR-T Clinical Trial Trends, Pre-2012-2018
6.3.1. Analysis by Trial Registration Year
6.3.2. Geographical Analysis by Number of Registered Trials
6.4. T-Cell Immunotherapies: Clinical Trial Overview
6.4.1. Clinical Trial Analysis: Distribution by Type of Product
6.4.2. Clinical Trial Analysis: Distribution by Phase of Development
6.4.3. Clinical Trial Analysis: Distribution by Patient Segment
6.4.4. Clinical Trial Analysis: Distribution by Type of Therapy

7. CHIMERIC ANTIGEN RECEPTOR-T CELL THERAPY
7.1. Introduction
7.2. History of Development
7.3. Key Opinion Leaders
7.4. Anatomical Layout of Chimeric Antigen Receptor
7.5. CAR-T Construction Analysis
7.6. Development of Chimeric Antigen Receptors
7.7. Development of CAR-T Cells
7.8. Universal CAR-Ts
7.9. Route of Administration
7.10. Toxicity Concerns
7.11. Management of Toxicity Issues
7.12. CD19: An Attractive Target
7.13. Other Targets
7.14. Challenges Associated with CAR-T Therapies
7.15. Kymriah/Tisagenlecleucel/CTL019 (Novartis)
7.16. Yescarta/Axicabtagene Ciloleucel/KTE-C19 (Kite Pharma)
7.17. JCAR (Juno Therapeutics)
7.18. CAR-T Series (Cellular Biomedicine Group)
7.19. CD19 CAR (Takara Bio)
7.20. Dual Targeting CAR-T Cell Therapies (Autolus)
7.21. CAR-T Therapies (Sinobioway Cell Therapy/The First Affiliated Hospital of Anhui Medical University)

8. T-CELL RECEPTOR (TCR) BASED THERAPIES
8.1. Chapter Overview
8.2. Structure of the T-Cell Receptor
8.3. Differences Between CAR and TCR
8.4. History of Development
8.5. Mechanism of Action
8.6. Key Opinion Leaders
8.7. Safety Concerns
8.7.1. Insertional Mutagenesis
8.7.2. On-Target, Off-Tumor Toxicity and Cross-Reactivity
8.7.3. TCR Mismatch Pairing
8.8. Prerequisites for Antigen-Specific T-Cell Receptors
8.9. Strategies to Enhance Antitumor Efficacy
8.9.1. Affinity Enhanced TCRs
8.9.2. Soluble TCR Based Biologics
8.10. SPEAR T-Cells (Adaptimmune)
8.10.1. Therapy Overview
8.10.1.1. NY-ESO SPEAR T-Cell
8.10.1.2. Mage-A10 T-Cell Therapy
8.10.1.3. AFP T-Cell Therapy
8.10.1.4. Mage-A4 T-Cell Therapy
8.10.2. History of Development
8.10.3. SPEAR T-Cells Technology Platform
8.10.4. Current Development Status
8.10.5. Key Clinical Trial Results
8.10.6. Dosage Regimen and Manufacturing
8.11. ALT-801 (Altor BioScience)
8.11.1. Therapy Overview
8.11.2. History of Development
8.11.3. Current Development Status
8.11.4. Key Clinical Trial Results
8.11.5. Dosage Regimen
8.11.6. Patent Portfolio
8.12. IMCgp100 (Immunocore)
8.12.1. Therapy Overview
8.12.2. Current Development Status
8.12.3. Key Clinical Trial Results
8.12.4. Dosage Regimen and Manufacturing
8.13. JTCR016 (Juno Therapeutics)
8.13.1. Therapy Overview
8.13.2. Current Development Status
8.13.3. Key Clinical Results
8.13.4. Dosage Regimen
8.14. CMD-602/WT1 TCR Therapy (Cell Medica)
8.14.1. Therapy Overview
8.14.2. History of Development
8.14.3. Current Development Status
8.14.4. Key Clinical Trial Results
8.14.5. Dosage Regimen and Manufacturing
8.15. TBI-1301 (Takara Bio)
8.15.1. Therapy Overview
8.15.2. Current Development Status
8.15.3. Key Clinical Trial Results
8.15.4. Dosage Regimen and Manufacturing

9. TUMOR INFILTRATING LYMPHOCYTES (TIL) BASED THERAPIES
9.1. Chapter Overview
9.2. History of Development
9.3. Key Opinion Leaders
9.4. Strategies to Enhance Efficacy
9.5. Prognostic Applications
9.6. Manufacturing Process
9.7. Autologous TIL Therapies (Iovance Biotherapeutics)
9.7.1. Therapy Overview
9.7.2. Current Development Status
9.7.2.1. LN-144
9.7.2.2. LN-145
9.7.3. Key Clinical Trial Results
9.7.4. Dosage Regimen and Manufacturing
9.7.5. Patent Portfolio
9.8. TIL (Nantes University Hospital)
9.8.1. Therapy Overview
9.8.2. Current Development Status
9.8.3. Key Clinical Trial Results
9.8.4. Dosage Regimen and Manufacturing
9.9. TIL (Netherlands Cancer Institute)
9.9.1. Therapy Overview
9.9.2. Current Development Status
9.9.3. Key Clinical Trial Results
9.9.4. Dosage Regimen and Manufacturing

10. KEY THERAPEUTIC AREAS FOR T-CELL THERAPIES
10.1. Chapter Overview
10.2. Hematological Malignancies
10.2.1. Leukemia and Lymphoma
10.2.1.1. Leukemia: Introduction and Epidemiology
10.2.1.1.1. Acute Myeloid Leukemia (AML)
10.2.1.1.2. Chronic Myeloid Leukemia (CML)
10.2.1.1.3. Acute Lymphocytic Leukemia (ALL)
10.2.1.1.4. Chronic Lymphocytic Leukemia (CLL)
10.2.1.2. Lymphoma: Introduction and Epidemiology
10.2.1.3. Current Treatment Landscape
10.2.1.3.1. Targeted Therapies
10.2.1.4. T-Cell Immunotherapy and Research Landscape
10.2.1.4.1. CAR-T Therapies and Leukemia/Lymphoma
10.2.1.4.2. TCR Therapies and Leukemia/Lymphoma
10.2.2. Multiple Myeloma
10.2.2.1. Introduction and Epidemiology
10.2.2.2. Current Treatment Landscape
10.2.2.3. T-Cell Immunotherapy and Research Landscape
10.3. Solid Tumors
10.3.1. Metastatic Melanoma
10.3.1.1. Introduction and Epidemiology
10.3.1.2. Current Treatment Landscape
10.3.1.3. T-Cell Immunotherapy and Research Landscape
10.3.1.3.1. TILs and Metastatic Melanoma
10.3.1.3.2. TCRs and Metastatic Melanoma
10.3.1.3.3. CAR-Ts and Metastatic Melanoma
10.3.2. Lung Cancer
10.3.2.1. Introduction and Epidemiology
10.3.2.2. Current Treatment Landscape
10.3.2.3. T-Cell Immunotherapy and Research Landscape
10.3.3. Bladder Cancer
10.3.3.1. Introduction and Epidemiology
10.3.3.2. Current Treatment Landscape
10.3.3.3. T-Cell Immunotherapy and Research Landscape
10.3.4. Kidney Cancer
10.3.4.1. Introduction and Epidemiology
10.3.4.2. Current Treatment Landscape
10.3.4.3. T-Cell Immunotherapy and Research Landscape
10.3.5. Ovarian Cancer
10.3.5.1. Introduction and Epidemiology
10.3.5.2. Current Treatment Landscape
10.3.5.3. T-Cell Immunotherapy and Research Landscape
10.3.5.3.1. CAR-Ts and Ovarian Cancer
10.3.5.3.2. TCRs and Ovarian Cancer
10.3.5.3.3. TILs and Ovarian Cancer
10.3.6. Breast Cancer
10.3.6.1. Introduction and Epidemiology
10.3.6.2. Current Treatment Landscape
10.3.6.3. T-Cell Immunotherapy and Research Landscape
10.3.6.3.1. CAR-Ts and Breast Cancer
10.3.6.3.2. TILs and Breast Cancer

11. EMERGING TECHNOLOGIES
11.1. Chapter Overview
11.2. Genome Editing Technologies
11.2.1. Technology Overview
11.2.2. Applications
11.2.3. Emerging Technology Platforms used in T-Cell Therapies
11.2.3.1. CRISPR/Cas9 System
11.2.3.1.1. Key Components and Function
11.2.3.1.2. Mechanism of Action
11.2.3.1.3. Targeting Efficiency and Challenges
11.2.3.1.4. Next-GEN CRISPR Technology
11.2.3.1.5. Technology Providers
11.2.3.1.5.1. Editas Medicine
11.2.3.1.5.2. Intellia Therapeutics
11.2.3.1.5.3. CRISPR Therapeutics
11.2.3.2. TALENs
11.2.3.2.1. Key Components and Function
11.2.3.2.2. Mechanism of Action
11.2.3.2.3. Advantages and Challenges
11.2.3.2.4. Technology Providers
11.2.3.2.4.1. Cellectis
11.2.3.2.4.2. Editas Medicine
11.2.3.3. megaTAL
11.2.3.3.1. Technology Providers
11.2.3.3.1.1. bluebird bio
11.2.3.4. Zinc Finger Nuclease
11.2.3.4.1. Technology Providers
11.2.3.4.1.1. Sangamo Therapeutics
11.3. Designing T-Cell Therapies with Improved Characteristics
11.3.1. Technologies for Targeting Multiple Cancers
11.3.1.1. Antibody Coupled T-Cell Receptor (Unum Therapeutics)
11.3.1.2. NKR-T Platform (Celyad)
11.3.2. Technologies for Improved Safety
11.3.2.1. Armored CAR and EGFRt Technology (Juno Therapeutics)
11.3.2.2. RheoSwitch Therapeutic System (Intrexon)
11.3.2.3. Inducible Caspase 9 Safety Switch (Bellicum Pharmaceuticals)
11.3.2.3.1. CaspaCIDe Technology
11.3.2.3.2. CIDeCAR Technology
11.3.2.3.3. GoCAR-T Technology
11.3.2.4. On-Off Switch, Multiple Companies
11.3.2.4.1. Inhibitory CAR (iCAR) (Juno Therapeutics)
11.3.2.4.2. On-Off Switch (Theravectys)
11.3.2.5. Other Technologies to Improve CAR-T Safety
11.3.2.6. Allogeneic Technologies
11.3.2.6.1. CIK CAR-T Cells (Formula Pharmaceuticals)
11.3.2.6.2. Allogeneic Platform (Celyad)
11.3.2.6.3. Allogeneic Platform (Cellectis)

12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Types of Partnership Models
12.3. T-Cell Immunotherapy Market: Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership Model
12.3.3. Analysis by Number of Partnerships (Most Active Industry Players)
12.3.4. Analysis by Number of Partnerships (Most Active Non-Industry Players)
12.3.5. Analysis by Type of Product
12.3.6. Analysis by Individual Products

13. FUNDING AND INVESTMENT ANALYSIS
13.1. Chapter Overview
13.2. Types of Funding
13.3. T-Cell Immunotherapy Market: Funding and Investment Analysis
13.3.1. Analysis by Number of Funding Instances
13.3.2. Analysis by Amount Invested
13.3.3. Analysis by Type of Funding
13.3.4. Analysis by Key Players

14. OTHER T-CELL IMMUNOTHERAPIES
14.1. Chapter Overview
14.2. Other T-Cell Immunotherapies
14.2.1. Distribution by Phase of Development
14.2.2. Distribution by Target Therapeutic Area
14.2.3. Distribution by Type of Cells
14.2.4. Distribution by Source of T-Cells
14.3. Treg Cell Therapy
14.3.1. Caladrius Biosciences
14.3.2. TxCell
14.3.3. TRACT Therapeutics
14.3.4. Cellenkos
14.3.5. Other Companies
14.4. T-Cell-based Vaccines
14.4.1. Immunovative Therapies
14.4.2. Acer Therapeutics
14.4.3. TVAX Biomedical
14.5. Virus-Driven T-Cell Therapies
14.5.1. Atara Biotherapeutics
14.5.2. Cell Medica
14.5.3. Tessa Therapeutics
14.6. Fucosylation Technology Platform
14.6.1. Targazyme
14.7. PD-1 Knockout Engineered T-Cell Therapy
14.7.1. Chengdu MedGenCell
14.7.2. Anhui Kedgene Biotechnology
14.7.3. Cell Biotech
14.8. TAC-T Cell Therapy
14.8.1. Triumvira
14.9. Gama Delta T-Cell Immunotherapy
14.9.1. GammaCell Bio-Technologies

15. CASE STUDY: CELL THERAPY MANUFACTURING
15.1. Chapter Overview
15.2. Introduction
15.3. Key Challenges
15.4. Current Trends
15.4.1. Companies with In-House Capabilities
15.4.2. Contract Manufacturers
15.5. Key Considerations for a Manufacturing Site
15.6. Regulatory Landscape

16. T-CELL IMMUNOTHERAPY: COST PRICE ANALYSIS
16.1. Chapter Overview
16.2. Factors Contributing Towards High Price Tags of Cell/Gene Therapies
16.3. Pricing Models for T-Cell Immunotherapies
16.3.1. On the Basis of Associated Costs
16.3.2. On the Basis of Competition
16.3.3. On the Basis of Patient Segment
16.3.4. On the Basis of Experts Opinions
16.4. Reimbursement Considerations for T-Cell Immunotherapies
16.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Therapy

17. MARKET SIZING AND OPPORTUNITY ANALYSIS
17.1. Chapter Overview
17.2. Scope and Limitations
17.3. Forecast Methodology
17.4. Overall T-Cell Immunotherapy Market, 2018-2030
17.4.1. T-Cell Immunotherapy Market: Distribution by Type of Therapy
17.4.2. T-Cell Immunotherapy Market: Distribution by Geography
17.4.3. T-Cell Immunotherapy Market: Distribution by Target Indications
17.5. T-Cell Immunotherapy Market: Product-Wise Sales Forecasts
17.5.1. Overall CAR-T Therapy Market
17.5.1.1. Kymriah (Novartis)
17.5.1.2. Yescarta (Gilead Sciences)
17.5.1.3. CD19 CAR-T (Sinobioway Cell Therapy/The First Affiliated Hospital of Anhui Medical University)
17.5.1.4. GPC3 CAR-T (Shanghai GeneChem)
17.5.1.5. TBI-1501/CD19 CAR-T (Takara Bio/Jichi Medical University)
17.5.1.6. JCAR017 (Juno Therapeutics/Celgene)
17.5.1.7. MB-CART19.1 (Miltenyi Biotec/Shanghai Children's Medical Center)
17.5.1.8. IM19 CAR-T (Beijing Immunochina Medical Science & Technology)
17.5.1.9. PCAR-019 (PersonGen BioTherapeutics)
17.5.1.10. AUTO2 (Autolus)
17.5.1.11. AUTO3 (Autolus)
17.5.1.12. BCMA CAR-T (The Beijing Pregene Science and Technology/Henan Cancer Hospital)
17.5.1.13. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology/Henan Cancer Hospital)
17.5.1.14. CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology/The First Affiliated Hospital of Soochow University)
17.5.1.15. LCAR-B38M CAR-T (Nanjing Legend Biotech)
17.5.1.16. CD19 CAR-T (Shanghai Bioray Laboratory)
17.5.1.17. bb2121 (Celgene/bluebird bio)
17.5.2. Overall TCR Therapy Market
17.5.2.1. IMCgp100 (Immunocore)
17.5.2.2. NY-ESO-1 TCR (Adaptimmune/GSK)
17.5.2.3. JTCR016 (Juno Therapeutics)
17.5.2.4. LTCR-H1-2 (Lion TCR, Agency for Science, Technology and Research, Third Affiliated Hospital, Sun Yat-Sen University)
17.5.2.5. ALT 801 (Altor Bioscience)
17.5.2.6. TBI-1301 (Takara Bio)
17.5.3. Overall TIL Therapy Market
17.5.3.1. TIL (Nantes University Hospital)
17.5.3.2. TIL (Netherlands Cancer Institute)
17.5.3.3. LN-144 (Iovance Biotherapeutics)
17.5.3.4. LN-145 (Iovance Biotherapeutics)

18. PROMOTIONAL ANALYSIS
18.1. Chapter Overview
18.2. Channels Used for Promotional Campaigns
18.3. Summary of Product Website Analysis
18.4. Summary of Patient Support Services and Informative Downloads
18.5. Kymriah: Promotional Analysis
18.5.1. Drug Overview
18.5.2. Product Website Analysis
18.5.2.1. Messages for Healthcare Professionals
18.5.2.2. Messages for Patients
18.5.3. Patient Support Services and Informative Downloads
18.5.4. Other Promotional Activities
18.5.4.1. Presence in Conferences
18.6. Yescarta: Promotional Analysis
18.6.1. Drug Overview
18.6.2. Product Website Analysis
18.6.2.1. Messages for Patients and Caregivers
18.6.2.2. Patient Support Services and Informative Downloads
18.6.3. Other Promotional Activities
18.6.3.1. Presence in Conferences

19. COMPANY PROFILES
19.1. Chapter Overview
19.2. Adaptimmune Therapeutics
19.3. Autolus
19.4. bluebird bio
19.5. CARsgen Therapeutics
19.6. Celgene
19.7. Cell Medica
19.8. Cellectis
19.9. Cellular Biomedicine Group
19.10. Immunocore
19.11. Innovative Cellular Therapeutics
19.12. Iovance Biotherapeutics
19.13. Kite Pharma (A Gilead Sciences Company)
19.14. Lion TCR
19.15. Novartis
19.16. Sinobioway Cell Therapy
19.17. Takara Bio
19.18. Unum Therapeutics
19.19. ZIOPHARM Oncology

20. CONCLUSION
20.1. With Steady Growth in the Development Pipeline, T-Cell based Therapies have Emerged as a Promising Segment of the Immunotherapy Market
20.2. Hematological Malignancies and Solid Tumors are Currently the Major Target Indications
20.3. The Competitive Landscape Features a Mix of Established Players and Start-ups, with Academic Institutes Spearheading Early-stage Development Activities
20.4. A Number of Novel Technology Platforms have also Emerged as Vital Enablers of Growth in this Market
20.5. Multiple Novel Types of Immunotherapies, other than CAR-T, TCR and TIL, are also Expected to Enter the Market in the Mid-Long Term
20.6. Increasing Partnership Activity and Financial Support from Various Investors are Indicative of the Lucrative Future Potential
20.7. The Premium Pricing of these Therapies Necessitate Appropriate Reimbursement and Promotional Strategies to Guarantee Commercial Success
20.8. Driven by the Approval of Two CAR-T Therapies and Encouraging Results of Late-stage Candidates, the Market is Expected to Grow Significantly in the Long Term

21. EXECUTIVE INSIGHTS
21.1. Chapter Overview
21.2. Cell Therapies
21.3. Celyad
21.4. Changhai Hospital
21.5. Iovance Biotherapeutics
21.6. Kite Pharma
21.7. Lion TCR
21.8. Theravectys
21.9. TxCell
21.10. University of Colorado
21.11. Waisman Biomanufacturing

22. APPENDIX 1: TABULATED DATA

23. APPENDIX 2: LIST OF COMPANIES

For more information about this report visit https://www.researchandmarkets.com/research/l6msck/tcell?w=12



            

Contact Data